Hypofractionation for prostate cancer and PROs
Menée auprès de 2 100 patients atteints d'un cancer de la prostate de stade T1b–T3aN0M0 traité par radiothérapie avec modulation d'intensité, cette étude évalue l'incidence de symptômes intestinaux auto-rapportés par les patients en fonction du schéma de fractionnement de la radiothérapie
In the non-inferiority CHHiP trial, 3216 patients underwent intensity-modulated radiotherapy for localised prostate cancer. The study compared conventional fractionation at a dose of 74 Gy in 37 fractions, previously assessed in the RT01 trial,1 with two moderately hypofractionated schedules: 60 Gy in 20 fractions and 57 Gy in 19 fractions, with fractions of 3 Gy per day. The quality-of-life (QoL) substudy by Anna Wilkins and colleagues2 describes the patient-reported outcomes (PROs) of 2100 patients, which were assessed with several QoL instruments.
The Lancet Oncology , commentaire en libre accès, 2014